Document is current
Any future updates will be listed below
-
Authors
Waskowiak, Pauline T.
de Jong, Brigit A.
Uitdehaag, Bernard M. J.
Saddal, Shalina R. D.
Aarts, Jip
Roovers, Aïda A. M.
van Oirschot, Pim
de Groot, Vincent
Schaafsma, Frederieke G.
van der Hiele, Karin
Ruitenberg, Marit F. L.
Schoonheim, Menno M.
Widdershoven, Guy A. M.
van der Veen, Sabina
Schippers, Esther C. F.
Klein, Martin
Hulst, Hanneke E.
,
van Munster, Casper E. P.
Wieberdink, Renske G.
Kragt, Jolijn J.
Schouten, Judith
Hoogervorst, Erwin L. J.
Bouma, Paul A. D.
De Kleermaeker, Floris G. C. M.
Holleman, Meike
Geurts, Sofie
de Brabander, Christaan
Kalkers, Nynke F.
den Teuling, Bram A. J.
Vermeer, Jos
Schouten, Chris C.
Stege, Gerard J.
van‘t Hullenaar, Thijs
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064)
- License Information
-
More Information
Article History
Received: 5 December 2023
Accepted: 8 December 2023
First Online: 13 January 2024
Declarations
:
: The Medical Ethical Committee of the Amsterdam UMC, Vrije Universiteit Amsterdam has reviewed and approved this study (METC 2021.0707, protocol version 2, 4 May 2022). Any future substantial changes to the study protocol will undergo review and approval by the METC. Written informed consent is obtained from all participants upon enrolment in the study.
: Not applicable.
: Pauline T. Waskowiak has no competing interests regarding publication.Brigit A. de Jong has no competing interests regarding publication.Bernard M.J. Uitdehaag has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics.Shalina R.D. Saddal has no competing interests regarding publication.Jip Aarts has no competing interests regarding publication.Aïda A.M. Roovers has no competing interests regarding publication.Pim van Oirschot is employed by Sherpa BV.Vincent de Groot has no competing interests regarding publication.Frederieke G. Schaafsma has no competing interests regarding publication.Karin van der Hiele has no competing interests regarding publication.Marit F.L. Ruitenberg has no competing interests regarding publication.Menno M. Schoonheim serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck.Guy A.M. Widdershoven has no competing interests regarding publication.Sabina van der Veen has no competing interests regarding publication.Esther C.F. Schippers has no competing interests regarding publication.Martin Klein has no competing interests regarding publication.Hanneke E. Hulst is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV.
